Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.61 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.61 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.61 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.61 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.61 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.61 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945708 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL13431268 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL195083 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL6021490 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL9410041 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL16668991 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL7055997 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL20241728 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| Methanesulfonamide SCHEMBL8296539 | 0.91 | MEN1 (0.83) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL13431280 | 0.89 | KDM4E (0.80) | MEN1KMT2AKDM4EGRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | claimed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | claimed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| CN-101563106-A | Combination of nmda- receptor ligand and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-10-21 | — | — | CN | claimed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | claimed |
| WO-2009000038-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD (AU) | 2008-12-31 | — | — | WO | claimed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | claimed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | claimed |
| EP-1903028-A1 | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects | Tschollar,, Werner (CH) | 2008-03-26 | — | — | EP | claimed |
| US-5192751-A | Administering a decahydroisoquinoline derivative | ELI LILLY AND COMPANY (US) | 1993-03-09 | — | — | US | claimed |
| US-4902695-A | ISOQUINOLINE DERIVATIVES; NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | claimed |
| JP-6183975-A | — | — | None | — | — | JP | disclosed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2025-07-15 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| US-5331001-A | ω-[2-(tetrazolylalkyl)cyclohexyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors | GUILFORD PHARMACEUTICALS INC. (US) | 1994-07-19 | — | — | US | disclosed |
| JP-H06183975-A | USE OF COMPETITIVE N-METHYL-D-ASPARTIC ACID RECEPTOR ANTAGONIST TO CURE INCONTINENCE OF URINE | ELI LILLY & CO | 1994-07-05 | — | — | JP | disclosed |
| EP-0383504-A2 | Decahydro isoquinoline derivatives, process for their preparation and use as medicines | ELI LILLY AND COMPANY (US) | 1990-08-22 | — | — | EP | disclosed |
| CN-1044816-A | Improvements relating to organic compounds | LILLY CO ELI (US) | 1990-08-22 | — | — | CN | disclosed |
| US-4902695-A | ISOQUINOLINE DERIVATIVES; NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | MEN1 1615/4885KMT2A 2257/4885KDM4E 4411/4885 |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | MEN1 3527/4885KMT2A 4757/4885KDM4E 4165/4885 |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | MEN1 1091/4885KMT2A 1202/4885KDM4E 2859/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | MEN1 1615/4885KMT2A 2257/4885KDM4E 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.